The findings strongly support that unecritinib should become one of the standards of care for NSCLC harboring ROS1 rearrangements, particularly those patients with baseline brain metastases or CD74-ROS1 fusions, and further clinical development of unecritinib for NSCLC with ALK rearrangement is warranted. Here, CD74 is linked to non-small cell lung carcinoma.